1454585-06-8

Usage

Uses

Used in Pharmaceutical Industry:
SR-3029 is used as an inhibitor for CK1δ and CK1ε for its potential role in treating cancer. The compound has shown to inhibit the proliferation of melanoma and breast cancer cell lines, making it a promising candidate for further research and development in the fight against cancer.
Used in Cancer Research:
In the field of cancer research, SR-3029 is used as a tool to study the role of CK1δ and CK1ε in cancer cell proliferation and tumor growth. Its selective inhibition of these kinases allows researchers to better understand the underlying mechanisms and potential therapeutic targets for cancer treatment.
Used in Drug Development:
SR-3029 is utilized in the development of new drugs targeting CK1δ and CK1ε, with the aim of creating more effective and targeted cancer treatments. Its potent and selective inhibition of these kinases makes it a valuable starting point for the design and synthesis of novel therapeutic agents.
Used in Preclinical Studies:
In preclinical studies, SR-3029 is used to evaluate its efficacy and safety in animal models, particularly in the context of breast tumor xenografts in mice. These studies provide valuable information on the potential of SR-3029 as a therapeutic agent in cancer treatment.

Upstream product

• 1446513-80-9 2,6-dichloro-9-(3-fluorophenyl)-9H-purine 
• 110-91-8 morpholine 
• 1454585-22-8 2-chloro-N-((4,5-difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-9H-purin-6-amine 
• 1201597-26-3 tert-butyl (4,5-difluoro-1H-benzo[d]imidazol-2-yl)methylcarbamate 
• 1201597-26-3 C₁₃H₁₅F₂N₃O₂ 
• 1446513-83-2 (4,5-difluoro-3H-benzo[d]imidazol-2-yl)methanamine hydrochloride 
• 768-35-4 3-fluorophenylboronic acid 
• 5451-40-1 2,6 dichloropurine 

Relevant academic research and scientific papers

Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer

Casein kinase 1δ/ε have been identified as promising therapeutic target for oncology application, including breast and brain cancer. Here, we described our continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1δ/ε inhibitors 17 and 28 displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple negative breast cancer cell line and have physical, in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers.

WEE1 DEGRADATION INHIBITORS

The invention provides compounds that inhibit the degradation of Weel. The compounds of the present invention are generally N-((1H-benzo[d]imidazol-2- yl)methyl)-9H-purin-6-amines. Compounds of the invention can be used for treatment of malconditions in p

Development of highly selective casein kinase 1δ/1ε (CK1δ/ε) inhibitors with potent antiproliferative properties

The development of a series of potent and highly selective casein kinase 1δ/ε (CK1δ/ε) inhibitors is described. Starting from a purine scaffold inhibitor (SR-653234) identified by high throughput screening, we developed a series of potent and highly kinas